INTRODUCTION
A severe but self-limited idiopathic variety of neutropenia, termed ''idiopathic neonatal neutropenia'', has been described among preterm infants. 1, 2 Neonates with this condition have several features in common, including the fact that no specific variety of neutropenia is diagnosed, it often appears late in the clinical course, can be quite prolonged, and generally occurs in otherwise well infants. 1, 2 It is not clear whether this condition is a single entity or represents multiple disorders with the common feature of severe but self-limited neutropenia. As neutropenia in preterm infants can be a sign of incipient severe illness, particularly sepsis, this variety of neutropenia in the neonatal intensive care unit (NICU) often causes concern, and sometimes prompts evaluations for infection and repeated or prolonged courses of antibiotics. 1, 2 We previously reported four patients with this variety of neutropenia, all with blood neutrophil counts less than 500 ml À1 . All responded to a 3-day course of recombinant granulocyte colonystimulating factor (rG-CSF) (10 mg/kg/day) with an increase in blood neutrophil counts. 1 Our investigations suggested that this variety was the result of reduced neutrophil production, which was not cyclic, not alloimmune, and not associated with recognized inborn errors, bacterial or viral infections, or medications.
The marrow neutrophil storage pool is a ready reserve of phagocytes that can be released into the circulation upon demand. Patients who have severe and prolonged neutropenia accompanied by few neutrophils in the marrow reserve have a significant deficiency in antibacterial defense. Such patients do not display a rapid increase in blood neutrophils following rG-CSF administration. It is not clear whether patients with ''idiopathic neonatal neutropenia'' have a rapid increase in blood neutrophils following rG-CSF administration, signifying an adequate neutrophil reserve, or rather whether such patients lack this response signifying the likelihood of a significant antibacterial defense deficiency.
Our four previous cases appeared to have an intact response to rG-CSF, suggesting adequate neutrophil reserves. However, it can be problematical to interpret serial blood neutrophil counts in neonates without a comparison group of placebo recipients. Therefore, we conducted a randomized, placebo-controlled trial of rG-CSF administration to patients with ''idiopathic neonatal neutropenia'' to assess the blood neutrophil response and thereby gain insight into the adequacy or inadequacy of their rG-CSFmobilizable marrow neutrophil reserves.
MATERIALS AND METHODS
From June 1, 1998 through July 1, 2001, patients in the NICU of the Shands Children's Hospital at the University of Florida underwent evaluation for neutropenia in accordance with our consensus document, ''A consistent approach to evaluating neutropenia in the NICU''. 3 Patients with a blood neutrophil count <500 ml À1 for more than two days, or <1000 ml À1 for more than 5 days, had maternal blood testing for antineutrophil antibodies. 4, 5 If those tests were negative, yet the neutropenia persisted with no diagnosis for the neutropenia, a marrow biopsy was performed using a micro-method we reported. 6 If no specific diagnosis for the neutropenia was still evident, the condition was termed ''idiopathic neonatal neutropenia'' 1 and the patient was eligible for this study.
After parental informed consent was obtained, eligible patients were randomized by the Shand's Hospital Research Pharmacist, using a random-number table, to receive either rG-CSF 10 mg/kg/ day i.v. over 30 minutes or placebo for 3 consecutive days. Study subjects had blood obtained for neutrophil concentrations at preset intervals: 24 h, 48 h, 72 hours, 5, 12, and 15 days after the first injection. Nosocomial infections between study entry and hospital discharge were diagnosed by the clinicians caring for the patients. No special infectious surveillance or cultures were part of this evaluation. Rather the hospital records were reviewed at discharge searching specifically for the diagnosis of nosocomial infection.
The study was approved by the Institutional Review Board of the University of Florida and by the University of Florida Clinical Research Center Advisory Committee. Informed consent included permission to use relevant clinical data recorded in the chart.
Data were analyzed by ANOVA, w 2 test, or Pearson's r correlation as appropriate. Results are reported as mean±SE, range and median. Significance was considered at p<0.05.
RESULTS
During the 3-year study period, 2407 infants were admitted to the NICU; 429 of these were less than 1500 g birth weight.
Demographics of the infants less than 1500 g are shown in Table 1 . Screening CBCs were not routinely performed; however, if an infant was noted to be neutropenic based on a clinically indicated CBC, they were evaluated according to our algorithm, ''A consistent approach to evaluating neutropenia in the NICU''. 3 This assessment included an evaluation for sepsis if clinically appropriate, and an appraisal for the presence of pregnancyinduced hypertension, intrauterine growth retardation, and maternal antibodies. If no etiology for the neutropenia was apparent and neutropenia persisted, a marrow biopsy was performed. After this evaluation, 14 infants were identified with ''idiopathic neonatal neutropenia''. In total, 10 were enrolled in this study, six of whom were male. None of the 10 were clinically ill at the time of study entry. Blood neutrophil counts on the day of study entry were 691±202 ml À1 . The gestational age of these infants (mean±SE) was 28.7±0.7 weeks, median 29, range 25 to 32 weeks, with birth weights of 1067±80 g, median 1136, range 741 to 1474 g. Apgar scores averaged 6 at 1 minute, and 7 at 5 minutes. Postnatal age of presentation with neutropenia ranged from 5 to 13 weeks (7.1±0.8 weeks, median 6.3 weeks). All had the diagnosis of ''idiopathic neonatal neutropenia'', in that none had positive neutrophil antibody tests, none were delivered to women with pregnancy-induced hypertension, and none had a recognized infectious disease at the time of study.
As part of our ''Consistent approach to neonatal neutropenia '', 3 all of these subjects with severe or prolonged neutropenia had a marrow biopsy. 3 In order to differentiate individuals with pseudoneutropenia due to excessive marginization, lidocaine with epinephrine was used as the topical anesthetic for these biopsies. Only one infant had a significant increase in circulating neutrophils after the procedure; the prebiopsy neutrophil count was 913 ml À1 , rising to 1596 ml À1 after the epinephrine exposure. Excessive neutrophil marginization (pseudo-neutropenia) was not thought to be a significant issue in these patients.
Marrow findings and the specifics of the neutrophil counts from all 10 subjects are shown in Table 2 . No specific diagnoses were evident from any marrow study. Eight had varying degrees of leftshifted myeloid maturation consistent with a consumptive process, and two had decreased neutrophil precursors consistent with decreased neutrophil production. Four of the marrow aspirates had increased B lymphocytes with decreased T lymphocytes.
rG-CSF was administered for 3 consecutive days to five infants, and placebo to five. Within 2 to 4 hours of rG-CSF administration, the absolute neutrophil count increased, and counts remained elevated, compared with placebo recipients, for at least 5 days Figure 1 ). On days 12 and 15, the counts of the two groups were similar. Prior to study, the neutropenia had persisted for between 18 and 63 days (Table 2 ). These infants underwent as many as six evaluations for sepsis during their period of neutropenia (range 2 to 6). No nosocomial infections were diagnosed in any of the subjects at the time of the neutropenia; however, sepsis was common during the entire hospitalization (Table 2) . After the initial randomization, one infant received multiple courses of rG-CSF for persistent neutropenia with ANC <500 ml À1 , and was discharged to home on rG-CSF twice a week.
DISCUSSION
Severe and prolonged neutropenia can constitute a significant host defense deficiency. 7 Indeed, children who have any of the varieties of severe chronic neutropenia, such as Kostmann syndrome, [8] [9] [10] cyclic neutropenia, 8, 11 Barth syndrome, 12 or Schwachman Diamond syndrome 13 are likely to have repeated bacterial 14 rG-CSF provides benefit to patients with severe chronic neutropenia by reducing their probability of acquiring an infection. 8, 9, 15 The role of rG-CSF is less clear among neonates who have severe but self-limited varieties of neutropenia, such as those with alloimmune neutropenia, [16] [17] [18] autoimmune neutropenia, 19, 20 the neutropenia of neonates born to women with severe pregnancyinduced hypertension, 21, 22 and ''idiopathic neonatal neutropenia''. 1, 2 Many different definitions for neutropenia in neonates have been proposed, including those by Xanthou 23 (1500 ml À1 ), 23 Manroe et al. 24 (1800 ml À1 ), and Mozinho et al. 25 (1100 ml À1 ). When defined as a circulating neutrophil concentration of less than 1500 ml À1 , neutropenia is a relatively common condition in the NICU, affecting between 6 and 58% of preterm infants. 2, 7, 26 One of the relevant issues in determining whether a particular variety of severe neutropenia conveys a risk for infectious acquisition is whether or not the marrow neutrophil reserve is adequate. For instance, individuals with ''pseudoneutropenia'', a condition where circulating neutrophils are chronically very low, but the marrow reserve is normal, do not have a host defense deficiency. In vivo studies, measuring neutrophil accumulation in skin or mucous membranes, indicate that such individuals are capable of mobilizing adequate quantities of neutrophils from the marrow reserve into sites of infection. 27 It is not clear whether the marrow neutrophil reserve is adequate among patients with ''idiopathic neonatal neutropenia''. The present study was designed to obtain this information, with respect to the rG-CSF-mobilizable marrow neutrophil reserves. To accomplish this study, we used a period of 3 years at one center. This was done with the cognizance that the number of study subjects would be very small, yet the consistent approach we had adopted at the University of Florida for evaluating neutropenia was helpful in insuring a uniform evaluation. 3 We observed that rG-CSF produced an immediate increase in blood neutrophil concentration. From this we conclude that the marrow reserves of these patients are not completely depleted. This interpretation is consistent with the reduced, but not depleted, marrow reserve we previously reported among four patients with this condition. 1 We observed that rG-CSF administration for 3 consecutive days effectuated a rapid and substantial increase in blood neutrophil counts that persisted for at least 5 days, but did not persist to 12 or to 15 days. We observed no clear benefit to rG-CSF administration among the five recipients, compared with the five placebo recipients, other than on blood neutrophil counts. However, the study was not powered to assess possible clinical benefits, but was focused on whether blood neutrophil counts increased, which clearly they did.
We conclude that the rG-CSF-mobilizable neutrophil reserves of patients with ''idiopathic neonatal neutropenia'' are adequate. This information suggests to us that this variety of neonatal neutropenia does not convey a high risk for infection. If we had observed a failure to respond to rG-CSF, we would have predicted an impaired antibacterial defense. Epidemiological studies will be needed to compare the rate of nosocomial infection among neonates who have this condition vs matched controls, but we predict that such rates will be similar and that ''idiopathic neonatal neutropenia'' can be considered a benign condition.
